Skip to content
  • Newsroom
  • Events
  • Contact
  • Home
  • Patients

    I need help with...

    • Understanding pelvic masses

      What is an adnexal mass and does it mean I have cancer?

    • Treatment plan options

      What testing is available to help map my treatment plan?

    • What to expect

      What do I need to know if my doctor orders one of your test kits?

    • Ongoing support

      Where can I turn for additional support?

    About Our tests

    Which test should I use?

    How do I tell my provider to order a test?

    Patient Resources

    Insurance & Billing

    Financial Assistance

    Pay a Bill

    Contact Us

  • Providers

    I need help with...

    • Assessing a pelvic mass

      What are the testing options available for pelvic masses?

    • Testing an indeterminate or likely benign pelvic mass

      Which test should I use if an unknown mass has been identified?

    • Testing a pelvic mass with planned surgery

      Which test should I use to assess my risk of malignancy before surgery?

    • How does the test work?

      What additional services do you provide?

    Order Test Kits

    Ova1Plus®

    OvaWatch®

    Scientific Publications

    FAQs

    Clinical Studies

    Your patient may qualify for a clinical trial, learn more →

    Provider Resources

    Order Test Kits

    Order Patient Materials

    Download Test Requisition Form

    Insurance & Billing

    Provider Events

  • Our Products
    • OvaWatch®
    • Ova1Plus®
  • About Us
    • About Us
    • Leadership
    • Careers
  • Research & Development
    • Pipeline
    • Clinical Study
    • Research and Professional Guidelines
  • Investors
    • Investor Overview
    • News
    • Events & Presentations
    • SEC Filings
    • Stock Information
    • Corporate Governance

Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women

By Gina | August 11, 2022

Study demonstrates the high clinical performance of a multivariate index assay in detecting early-stage ovarian cancer in Filipino women, highlighting its potential as a valuable risk assessment tool for this population.

Read More

Ethnic Disparity in Clinical Performance Between Multivariate Index Assay and CA-125 in Detection of Ovarian Malignancy

By Gina | August 9, 2019

Examination of the ethnic disparities in the performance of multivariate index assay compared to CA125 in detecting ovarian malignancies.

Read More

Multivariate Index Assay Is Superior to CA-125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women

By Gina | May 8, 2019

This study shows the superiority of the multivariate index assay over CA125 and HE4 tests in detecting ovarian malignancies in African-American women.

Read More

Recent Posts

  • Aspira Women’s Health Announces Appointment of Ellen Beausang to the Board of Directors
  • Aspira Women’s Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations
  • Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
  • Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award
  • Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results

Recent Comments

    Archives

    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Search

    Footer

    Have a question?

    Tel: 844-ASPIRA1 (844-277-4721)

    Fax: 866-283-3634

    12117 Bee Caves Road
    Building III, Suite 100
    Austin, TX 78738

    Investors

    Investor Overview

    Events & Presentations

    SEC Filings

    Corporate Governance

    Stock Information

    Providers & Practices

    Provider Overview

    Research and Professional Guidelines

    Clinical Studies

    Pipeline

    Patients & Individuals

    Patient Overview

    Insurance & Billing

    Bill Pay

    Resources

    News

    Educational Events

    FAQs

    About

    About Aspira

    Leadership

    Licensure & Legal

    Code of Conduct

    Aspira Synergy

    © 2023-2025 Aspira Women's Health. All Rights Reserved.

    Privacy Policy. Terms of Use.

    • Home
    • Patients
    • Providers
    • Our Products
      • OvaWatch®
      • Ova1Plus®
    • About Us
      • Our Story
      • Leadership
      • Careers
    • Research and Development
      • Pipeline
      • Clinical Study
      • Research and Professional Guidelines
    • Investors
      • Investor Overview
      • News
      • Events & Presentations
      • SEC Filings
      • Stock Information
      • Corporate Governance